<DOC>
	<DOCNO>NCT02652416</DOCNO>
	<brief_summary>Safety tolerability BI 1026706 healthy Chinese Japanese male subject follow oral administration single rise dos ( SRD ) follow multiple rising dos ( MRD )</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics BI 1026706 Healthy Chinese Japanese Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Chinese ethnicity Japanese ethnicity , accord follow criterion : Chinese ; bear China ethnic Chinese born outside China , descendent 4 ethnic Chinese grandparent born China Japanese ; bear Japan , live outside Japan &lt; 10 year , parent grandparent born Japan Age 20 45 year ( incl . ) BMI 18.5 25 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation . Male subject agree minimize risk female partner become pregnant fulfilling follow criterion start least 30 day first administration trial medication 30 day trial completion : Use adequate contraception , e.g . follow method plus condom : combined oral contraceptive , intrauterine device Vasectomised ( vasectomy least 1 year prior enrolment ) Surgically sterilise ( include hysterectomy ) female partner Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection include HIV , viral hepatitis ( ) tuberculosis evidence tuberculosis infection define positive QuantiFERON TBGold ( TSPOT ) test . Subjects positive QuantiFERON TBGold ( TSPOT ) test may participate study work ( accord local practice/guidelines ) establish conclusively subject evidence active tuberculosis . If presence latent tuberculosis establish , treatment must initiate maintain accord local country guideline . History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake biologic agent current study medication drug consider likely interfere safe conduct study Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval Participation another trial ( include bioequivalence trial ) investigational drug within 90 day 5 halflives ( whichever great ) prior plan administration trial medication Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 30 g per day ) Drug abuse positive drug screen Blood donation 200 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Have receive live bacterial live viral vaccination 12 week prior date screening . Subjects must agree receive live bacterial live viral vaccination study 12 month last administration study drug Have receive Bacille CalmetteGuerin ( BCG ) vaccination 12 month prior date screening . Subjects must agree receive BCG vaccination study 12 month last administration study drug Male patient agree minimize risk female partner become pregnant least 30 day first administration trial medication 30 day trial completion . Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>